All articles by admin-demo

admin-demo

US pharma industry IT recruitment activity rises 0.3% in July 2021

The US pharma industry registered a 0.3% rise in IT hiring activity in July 2021 compared with the previous month,…

US pharma industry IT recruitment activity rises 0.3% in July 2021

The US pharma industry registered a 0.3% rise in IT hiring activity in July 2021 compared with the previous month,…

Asia-Pacific’s pharma industry IT hiring activity rises 18.9% in February 2021

Asia-Pacific witnessed an 18.9% rise in IT hiring activity in the pharma industry in February 2021 compared with the previous…

North America’s pharma industry IT hiring activity rises 2.4% in February 2021

North America witnessed a 2.4% rise in IT hiring activity in the pharma industry in February 2021 compared with the…

IT hiring in global pharma industry rises 6.1% in February 2021

The global pharma industry noticed a 6.1% rise in IT hiring activity in February 2021 over the previous month, led…

Covid-19 live timeline

Here’s the timeline of how the Coronavirus outbreak evolved from Wuhan city in China and is spreading across the world and how it affects the power industry.

Is a robot about to steal my job?

Future of Work 2019: The pace of change is certainly faster than the industrial revolution, but changes are likely to occur over 20 to 40 years.

Future of semiconductor industry: Ten companies predicted to succeed

Intel is the company which is best placed to succeed in the semiconductor sector, according to exclusive theme-based analysis.

ARCA biopharma to study Gencaro in Phase III trial

ARCA biopharma has announced plans to investigate Gencaro (bucindolol hydrochloride) as a genetically-targeted therapy in a pivotal Phase III clinical trial for atrial fibrillation (AF) in patients with a certain type of heart failure (HF).

BeiGene doses first patient in Phase II trial of zanubrutinib

BeiGene has dosed the first patient in a global Phase II trial to evaluate the efficacy of zanubrutinib for the treatment of relapsed or refractory (R/R) marginal zone lymphoma (MZL).